{"id":2204,"date":"2020-02-14T12:49:49","date_gmt":"2020-02-14T12:49:49","guid":{"rendered":"http:\/\/lonecandle.com\/?p=2204"},"modified":"2020-02-14T12:49:49","modified_gmt":"2020-02-14T12:49:49","slug":"trump-called-on-congress-to-pass-a-drug-prices-bill-democrats-reminded-him-they-already-did","status":"publish","type":"post","link":"https:\/\/lonecandle.com\/?p=2204","title":{"rendered":"Trump called on Congress to pass a drug prices bill. Democrats reminded him they already did."},"content":{"rendered":"\n

\n\n“The House bill \u2014 H.R.3 \u2014 has a few mechanisms<\/a> for reducing prescription drug prices, but most notably, it would allow the US health department to directly negotiate the prices it will pay for up to 250 drugs every year. The Congressional Budget Office (CBO) has estimated the bill would save Medicare up to $450 billion over 10 years because of those new negotiating powers. CBO has also projected about eight fewer drugs (out of an expected 300 over 10 years) would come to the market in the next decade because of the decrease in revenues for drug makers.
<\/p>\n\n\n\n

Despite Trump\u2019s promises on the 2016 campaign trail that he would support proposals allowing Medicare drug negotiations, the White House threatened to veto the House plan. They called it a plan to institute government \u201cprice controls,\u201d and said it would limit access to medicine, a favored talking point of the pharmaceutical lobby.Even without this veto threat, H.R.3 is expected to be dead-on-arrival in the Senate. Senate Majority Leader Mitch McConnell has shown no interest in taking up the bill.”
…
“Instead, Trump has aligned himself more with Republican Sen. Chuck Grassley, who has advanced a narrower set of reforms from his perch as the Senate Finance Committee chair. (Grassley has also accused<\/a> McConnell of sabotaging his bill, which moved out of Grassley\u2019s committee with bipartisan support.)
<\/p>\n\n\n\n

His committee sent a bill to the full Senate in the fall, though it has languished there in the months since. It\u2019s unclear if Trump\u2019s quasi-endorsement \u2014 he did not call out Grassley\u2019s bill directly Tuesday night, instead praising the senator generally for his individual work on the issue \u2014 will provide any new momentum for the plan. Grassley\u2019s bill, as the Brookings Institution documented<\/a>, achieves pricing reform through a mix of technical changes to the rebates that drug makers pay under Medicare and Medicaid as well as provisions to cap out-of-pocket drug costs for seniors.<\/p>\n\n\n\n

Right now, neither of the bills seems on a fast track to anywhere. Part of this is because Trump\u2019s interest in drug pricing has been scattershot at best, and many Republicans are reluctant to place too many new regulations on an innovation industry.”
https:\/\/www.vox.com\/policy-and-politics\/2020\/2\/5\/21123917\/state-of-the-union-democrats-chanting-hr3-bill<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

“The House bill \u2014 H.R.3 \u2014 has a few mechanisms for reducing prescription drug prices, but most notably, it would allow the US health department to directly negotiate the prices it will pay for up to 250 drugs every year. The Congressional Budget Office (CBO) has estimated the bill would save Medicare up to $450 billion over 10 years because of those new negotiating powers. CBO has also projected about eight fewer drugs (out of an expected 300 over 10 years) would come to the market in the next decade because of the decrease in revenues for drug makers.<\/p>\n

Despite Trump\u2019s promises on the 2016 campaign trail that he would support proposals allowing Medicare drug negotiations, the White House threatened to veto the House plan. They called it a plan to institute government \u201cprice controls,\u201d and said it would limit access to medicine, a favored talking point of the pharmaceutical lobby.<\/p>\n

Even without this veto threat, H.R.3 is expected to be dead-on-arrival in the Senate. Senate Majority Leader Mitch McConnell has shown no interest in taking up the bill.”<\/p>\n

…<\/p>\n

“Instead, Trump has aligned himself more with Republican Sen. Chuck Grassley, who has advanced a narrower set of reforms from his perch as the Senate Finance Committee chair. (Grassley has also accused McConnell of sabotaging his bill, which moved out of Grassley\u2019s committee with bipartisan support.)<\/p>\n

His committee sent a bill to the full Senate in the fall, though it has languished there in the months since. It\u2019s unclear if Trump\u2019s quasi-endorsement \u2014 he did not call out Grassley\u2019s bill directly Tuesday night, instead praising the senator generally for his individual work on the issue \u2014 will provide any new momentum for the plan. Grassley\u2019s bill, as the Brookings Institution documented, achieves pricing reform through a mix of technical changes to the rebates that drug makers pay under Medicare and Medicaid as well as provisions to cap out-of-pocket drug costs for seniors.<\/p>\n

Right now, neither of the bills seems on a fast track to anywhere. Part of this is because Trump\u2019s interest in drug pricing has been scattershot at best, and many Republicans are reluctant to place too many new regulations on an innovation industry.”<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[13],"tags":[440,221,439,72,50,70,384,75,170],"class_list":["post-2204","post","type-post","status-publish","format-standard","hentry","category-article-share","tag-bills","tag-donald-trump","tag-drugs","tag-high-medical-prices","tag-medical","tag-medical-prices","tag-price","tag-price-of-healthcare","tag-trump"],"_links":{"self":[{"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/posts\/2204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lonecandle.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2204"}],"version-history":[{"count":1,"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/posts\/2204\/revisions"}],"predecessor-version":[{"id":2205,"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/posts\/2204\/revisions\/2205"}],"wp:attachment":[{"href":"https:\/\/lonecandle.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lonecandle.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lonecandle.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}